A "successful change" was defined as initiation of a recommended therapeutic alternative within 90 days of the fax alert for the 13 PDDIs.
We determined values of these predictor variables that are associated with significant changes in absorbance, where a significant change was defined as one in which the absorbance exceeded two SDs for the no-leak condition.
A clinically significant change was defined by a change in category; the different categories are defined as follows: normal (0 6), mild (7 10), moderate (11 13), severe (14 and above).
A clinically relevant change was defined as a change from the mean of each variable to a mean outside the reference range.
On the basis of studies of the biological variation of cTn and data from previous chest pain cohort studies, a significant absolute change was defined as a rise or fall of at least 10 ng/L within 6 hours.
We also evaluated colorectal cancer risk in relation to creatinine-adjusted urinary 1-OHPG concentration as a continuous variable; as in previous studies [ 15], a one unit change was defined as half the difference between the 25th and 75th percentile measurements in controls.
A significant weight change was defined as 10 pounds or 4 kg.
A treatment decision change was defined as any change from before MP recommendation to actual treatment received.
We have updated the manuscript with the following: 1) Defining how a primary outcome change was defined.
A significant size change was defined to be ≥5 mm change for popliteal cysts and ≥2 mm for other lesions.
